IL112046A0 - Methods of inhibiting obsessive-compulsive and consumptive disorders - Google Patents

Methods of inhibiting obsessive-compulsive and consumptive disorders

Info

Publication number
IL112046A0
IL112046A0 IL11204694A IL11204694A IL112046A0 IL 112046 A0 IL112046 A0 IL 112046A0 IL 11204694 A IL11204694 A IL 11204694A IL 11204694 A IL11204694 A IL 11204694A IL 112046 A0 IL112046 A0 IL 112046A0
Authority
IL
Israel
Prior art keywords
compulsive
methods
obsessive
inhibiting
consumptive disorders
Prior art date
Application number
IL11204694A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL112046A0 publication Critical patent/IL112046A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IL11204694A 1993-12-21 1994-12-19 Methods of inhibiting obsessive-compulsive and consumptive disorders IL112046A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16848393A 1993-12-21 1993-12-21

Publications (1)

Publication Number Publication Date
IL112046A0 true IL112046A0 (en) 1995-03-15

Family

ID=22611670

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11204694A IL112046A0 (en) 1993-12-21 1994-12-19 Methods of inhibiting obsessive-compulsive and consumptive disorders

Country Status (12)

Country Link
EP (1) EP0659428A1 (ja)
JP (1) JPH07196494A (ja)
KR (1) KR950016739A (ja)
CN (1) CN1109331A (ja)
AU (1) AU8155694A (ja)
CA (1) CA2138458A1 (ja)
CZ (1) CZ322494A3 (ja)
HU (1) HUT71466A (ja)
IL (1) IL112046A0 (ja)
NO (1) NO944910L (ja)
RU (1) RU94044323A (ja)
ZA (1) ZA9410076B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
IL115613A0 (en) * 1994-10-20 1996-01-19 Lilly Co Eli Bicyclic neuropeptide y receptor antagonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes

Also Published As

Publication number Publication date
ZA9410076B (en) 1996-06-19
HU9403656D0 (en) 1995-02-28
JPH07196494A (ja) 1995-08-01
CZ322494A3 (en) 1995-08-16
NO944910D0 (no) 1994-12-19
CN1109331A (zh) 1995-10-04
EP0659428A1 (en) 1995-06-28
NO944910L (no) 1995-06-22
AU8155694A (en) 1995-06-29
KR950016739A (ko) 1995-07-20
RU94044323A (ru) 1996-11-10
CA2138458A1 (en) 1995-06-22
HUT71466A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
HU9401580D0 (en) Method for the preparation and popification of alphia - interferon
GB9414493D0 (en) Improved sunglasses and safety eyewear and method of making the same
GB2294465A8 (en) Perfluoroelastomeric compositions and methods
HUT75317A (en) Treatment of obsessive-compulsive disorders with 5-ht2 antagonists
ZA9410083B (en) Methods of inhibiting autoimmune diseases
EP0729300A4 (en) FAS PROTEIN AND METHOD FOR ITS USE
EP0711168A4 (en) METHOD FOR TREATING VPN APOPTOSE AND RELATED ITEMS
ZA9410088B (en) Methods of inhibiting breast disorders
PL312470A1 (en) Method of oximation
EP0709420A3 (en) Block copolymers of polyesters and polycarbonates and process for their preparation
EP0714511A4 (en) METHOD FOR DETERMINING AND COMBATING DISTURBANCES OF THE CENTRAL VENEER SYSTEM
PL313740A1 (en) Method of
ZA9410076B (en) Methods of inhibiting obsessive-compulsive and consumptive disorders
HU9403422D0 (en) Methods of inhibiting the effects of amyloidogenic proteins
GB9401574D0 (en) Clock distributing methods and apparatus
EP0781140A4 (en) FACTOR INHIBITING THE CORTICOTROPIN RELEASE AND METHOD FOR ITS USE
PL305244A1 (en) Method of obtaining ethyanol and isopropanol
PL302250A1 (en) Purified form of streptogramines, method of obtaining same and pharmaceutical agents containing it
GB2275314B (en) Support member and method of use
HU9401158D0 (en) Method for manufacturing of bearer-ribbon and bearer-ribbon
GB9316880D0 (en) Method of grinding
ZA943486B (en) Fining method and agents
GB9307438D0 (en) Method and inhibiting hydrate formation
GB9301476D0 (en) Doors and methods of forming doors
GB9309926D0 (en) Composition and method of treating skin disorders